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Abstract 
Background: The last few decades have seen the rising global acknowledgment of the importance of ethics in 
the conduct of health research. But research ethics committees or institutional review boards (IRBs) have also been 
criticized for being barriers to research. This article examines the case of the Philippines, where little has been done to 
interrogate the health research and IRB culture, and whose circumstances can serve as reflection points for other low‑ 
and middle‑income countries.
Methods: Semi‑structured interviews were conducted from July to October 2020 to elicit health researchers’ 
perspectives and experiences regarding IRBs and the ethics approval process in the country, as well as counterpoint 
narratives from researchers who have also worked for IRBs.
Results: Across the fields of clinical, public health, and social science research, the issue of ethics review revealed 
itself to be foremost an issue of inequity. IRB processes serve as a barrier for those outside the academe; those belong‑
ing to institutions, cities, or entire regions without their own accredited IRBs; and researchers working independently, 
without ample budget, or on highly specialized topics—more so for non‑clinical researchers who must grapple with 
the primarily biomedical framework of most IRBs. Consequently, the research landscape invariably favors those with 
the resources to do research, and  researches that tend to attract funding.
Conclusion: The broader challenge of equity in health research will entail more fundamental reforms, but proximal 
interventions can be done to make the ethics approval process more equitable, such as enhancing institutional 
oversight, regulating IRB fees, and enabling a more supportive and welcoming environment for early‑career, student, 
independent, and non‑clinical health researchers. This article ends by reflecting on the implications of our findings 
toward the larger research culture.
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inequity, Philippines
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Background
The past few decades have witnessed an increasing 
acknowledgment of the importance of ethics in the con-
duct of human research. Consequently, professional 
organizations and academic institutions around the 
world have organized ethical guidelines and review com-
mittees (here on alternately referred to as ethics boards or 
institutional review boards [IRBs]) to ensure researchers’ 
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adherence to ethical principles. As such, securing ethics 
approval has become essential to the initiation, funding, 
and publication of health research.
But IRB processes have also been criticized for being a 
barrier to research. Examining two multi-center Austral-
ian researches, Barnett et  al. found high costs—both in 
terms of time and money—in obtaining ethics approval 
[1]. Kendall and Halliday highlighted particular issues 
faced by qualitative researchers, including the chal-
lenges posed by a “biomedical research ethics paradigm” 
to researchers with “a social justice agenda.” [2] (p. 308) 
Summarizing concerns raised by existing scholarship, 
Nicholls et al. wrote:
While few would disagree with the general need for 
ethics review, existing review processes are often 
criticized; common complaints include the amount 
of paperwork required, inconsistency of decisions 
between review boards, and suggestions that eth-
ics review systems may not be equipped to properly 
review specific types of research [3].
Nicholls et  al. further underscored the absence of 
“gold standards against which to evaluate research ethics 
review processes”; and, crucially for the Philippine con-
text, how “there has been little in the way of published 
research on the subject of assessment of research eth-
ics review.” [3] In fact, a quick PubMed search, coupled 
with our preliminary library research, revealed no studies 
dealing with this topic in the Philippines.
Following the above and other researches, we set out 
to examine the ethics approval process in the Philippines 
according to these three questions:
1. How are demands for ethical research struc-
turing the health research landscape?;
2. What are the experiences and particular chal-
lenges of Filipino health researchers with regards to 
IRBs?; and
3. How exactly do researchers from specific dis-
ciplines (e.g. clinical researchers versus social scien-
tists) feel about ethics and IRBs?
Our study builds a preliminary knowledge base—and 
not necessarily an exhaustive picture—for this particular 
topic in the Philippines. Through qualitative interviews 
that elicited the perspectives and experiences of Fili-
pino researchers themselves, as well as people involved 
in Philippine IRBs, this study charts the ethics approval 
process in the country and identifies contemporary bar-
riers and facilitators along the way. Building on this data, 
we offer policy recommendations for academic institu-
tions, IRBs, and government bodies that not only speak 
to the situation of health research in the Philippines, but 
are also relevant to other contexts, especially in low- and 
middle-income countries where researchers and institu-
tions alike have likewise adapted to the demands of ethics 
in research.
Ethics review in the Philippines
Relative to the Global North, the institutionalization of 
research ethics processes in the Philippines is a fairly late 
trend. In the late 1980s, for example, IRBs were already 
present in over 60 percent of hospitals in the United 
States [4]; while by 2000, “more than 95% of Portuguese 
hospitals had established” an IRB [5] (p. 485).
In contrast, in the 1980s the Philippines was only see-
ing the formation of a National Ethics Committee, tasked 
to “promote ethics review in health research.” [6] Within 
that decade, the only major academic or research institu-
tion in the country with a self-run IRB was the Research 
Institute for Tropical Medicine under the Department of 
Health (DOH) [7]. By the early 2000s, “only 50 percent of 
[Philippine] institutions [had] an [IRB].” [8] (p. 24).
In 2006, the Philippine Health Research Ethics Board 
(PHREB) was officially established. Consisting of mem-
bers from various research disciplines, the board’s 
mandate includes overseeing the establishment and per-
formance of IRBs in the country, as well as “[networking] 
with relevant local, national and international organiza-
tions.” [9] As of January 2021, the PHREB website lists 
104 accredited IRBs in the country, 40 of which are found 
in the capital region of Metro Manila.
The country’s leading academic institutions estab-
lished their own IRBs only within the last 15 years—for 
example, in 2010 for the University of the Philippines 
(UP) Manila, which houses the National Institutes of 
Health and is widely considered the country’s premiere 
health-sciences university [10]; and in 2015 for Ateneo de 
Manila University [11]. For the social sciences, the coun-
try’s mother organization, the Philippine Social Science 
Council, instituted its dedicated IRB only in 2017 [12].
Significantly, the Single Joint Research  Ethics Board 
(SJREB) was formed under the DOH in 2017. Tailored 
specifically to ease the ethics approval process for mul-
tisited studies, the SJREB is the closest to a one-size-fits-
all mechanism for multisited protocols in the country, 
in that it furnishes such protocols with blanket approval 
applicable to all hospitals under the DOH, allowing 
researches to proceed with data gathering without need-
ing to obtain separate approval for each site [13].
Methodology
From July to October 2020, we conducted semi-struc-
tured interviews with a total of 40 researchers in the 
Philippines. Because of the coronavirus disease 2019 
(COVID-19) pandemic, we had to conduct the study 
remotely; at the time, our team members, all health 
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researchers with experience in qualitative work, were 
each based in a different part of the country. Heed-
ing Mays and Pope’s [14] call for purposive, theoreti-
cally informed sampling, and drawing on what Marshall 
describes as the “researchers’ practical knowledge of the 
research area,” [15] (p. 523) we purposively recruited our 
participants through peer referrals and targeted searches 
via Google Scholar, keeping the list as inclusive as pos-
sible so long as the interviewee was relevant to the ethics 
review process (e.g. as a researcher, board member, jour-
nal editor, government health official, hospital residency 
training officer). However, navigating the ‘new normal’ 
of the pandemic, and the changes it imposed upon aca-
demia and research culture, meant that realistically we 
had to simplify our participant selection and also con-
sider the fact that our potential interviewees—all fel-
low researchers—were imaginably in similar straits with 
regards to adjusting to the pandemic. As such, for ease of 
access, we first approached individuals who were already 
known to us (e.g. at work), either through phone call, 
text message, or e-mail, before blindly contacting those 
with whom we were completely unacquainted. Prior to 
the interviews, our participants were sent the interview 
guides for their perusal; this preliminary correspond-
ence also served as an avenue for them to raise questions 
about the study or concerns regarding their participation.
We initially categorized our participants accord-
ing to three major disciplines: clinical research, public 
health research, and social science research. IRB mem-
bers constituted a fourth category, and key inform-
ants—ranging from journal editors, heads of private 
research firms, to past and present government officials 
in health- and research-related fields—constituted the 
fifth. However, many participants did not necessar-
ily belong to only one category, thus accounting for 
the participant distribution according to discipline 
exceeding the total number of actual participants. Save 
for three participants—two from the Northern Mind-
anao region and one from Cavite province—all inter-
viewees were based in Metro Manila. Nearly half were 
affiliated with the UP system. Fifteen participants were 
early-career researchers (including graduate students), 
while the rest were considered established research-
ers. Data saturation became our determinant for the 
final sample size: During data gathering, our team regu-
larly consulted with one another regarding the findings 
of an interview in order to determine whether we had 
attained some form of data saturation in each category 
of interviewees. Cognizant of our study’s aim to pro-
vide a preliminary—and not necessarily a definitive or 
exhaustive—picture of our subject matter, we would 
still encounter considerable saturation usually by the 
10th interviewee, after which we would cap interviews 
for that category. In the end, our selection also con-
sidered a gender balance, workplace affiliation, and 
research discipline, all summarized in Table 1.
Our remote interviews were conducted either 
through phone call or video-conferencing software 
like Zoom.  This capability to participate in a remote 
interview became our sole exclusion criterion. These 
interviews usually took 30 to 45  min. Although the 
interviews followed a general format—one that began 
with the interviewee’s personal experiences (e.g. their 
professional background, their individual experiences 
in research and with IRBs) before transitioning to more 
general topics like their views on ethical research, 
IRB practices in the country, and the impact of IRBs 
on research culture—we still tailored our questions 
according to the participant’s background and there-
fore used four separate guides (see Additional file 1 for 
the final interview guides). To reduce bias during the 
interviews, given that our team members all had prior 
interactions with IRBs, we strove as much as possible to 
follow the interview guide, sticking to one open-ended 
question at a time, and to remember that we were there 
as interviewers only, and not co-generators of insight. 
Our initial interviews served as pilot tests, but as we 
conducted more interviews, we also adjusted and 
tweaked specific questions that were inconspicuously 
biased, as well as allowed the participant’s response to 
shape succeeding or follow-up questions.
Consent forms were signed electronically; like-
wise, participant tokens were delivered via an online 
medium. The audio copies of the interviews were sent 
to transcribers who had signed nondisclosure agree-
ments, and upon receiving the finished transcripts, our 
research team proceeded to ensure participant ano-
nymity by removing as much identifying information as 
Table 1 Description of participant characteristics
Distribution according to gender
 Male 21
 Female 19
Distribution according to research discipline
 Clinical research 13
 Public health research 11
 Social science research 14
 IRB member 10
 Key informant 5
Distribution according to affiliation
 University of the Philippines system 17
 Private universities or teaching hospitals 10
 Nongovernment research firms 9
 Others 4
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possible in each transcript. Only our research team has 
access to all 40 transcripts, which have been secured in 
a password-encrypted folder.
All transcripts were uploaded to a secure, offline 
NVivo 10.0 database and approached by way of deduc-
tive thematic analysis. Guided by our literature review, 
our research team first read the transcripts individually 
to come up with initial codes. We consulted with our 
team members regularly to ensure our individual read-
ings of the text were devoid of researcher bias. Compar-
ing codes led to our preliminary themes, after which we 
did another round of reading to arrive at the final themes 
by consensus. Our study was approved by the UP Manila 
Research Ethics Board (UPMREB 2019–259-01).
Results
Across all three sectors of health research, researchers are 
one in recognizing the importance of ethics in the con-
duct of their work. All our clinical researchers, for exam-
ple, agreed that it is now safer than ever to conduct trials 
precisely because IRBs exert rigid measures in evaluating 
protocols. But such procedural rigidity has also been crit-
icized, with one participant describing the whole applica-
tion process as “intimidating.” In this section, we discuss 
these criticisms and offer perspectives from researchers 
who are also IRB members, with particular attention to 
the differences among the three sectors.
Ethics review takes a long time
The researchers’ most common and prominent com-
plaint is that the review process in the Philippines is 
time-consuming. According to them, it takes anywhere 
between two weeks to a month from the time of proto-
col submission before IRBs even give an initial decision, 
and between two to three months before a final decision 
can be reached. Accounting for protocol revisions and 
resubmissions, the whole process can sometimes last 
as long as “almost a year,” disrupting research timelines 
even when a long process has been anticipated. A public 
health researcher said a project she was involved in was 
delayed for almost a year only because the protocol was 
not approved immediately—despite zero requests for 
revisions from the reviewers. Separately, a consultant at a 
tertiary training hospital shared:
Our hospital was supposed to participate in an 
international clinical trial. But it took a long time 
for the ethics board to approve the study that by the 
time we got approval, the trial was about to close. 
We ended up withdrawing our participation.
As the latter quote suggests, the time-consuming 
nature of the review process is of great concern particu-
larly for researchers who are working on urgent studies 
or operating on a limited timeline. A head of a private 
research firm counted at least three recent instances of 
potential international collaborators backing out of a 
Philippines-based study for this reason alone. Even non-
professional settings experience similar constraints: A 
university professor talked of instances when students 
got delayed or had to drop out simply because their the-
sis proposals were not approved promptly. Consequently, 
researchers are either forced to meticulously account for 
the estimated review duration in structuring their stud-
ies—or altogether abandon certain aspects of proposed 
projects, if not their entirety, that cannot afford longer 
time frames.
Another impact is that, within the health research 
community in the Philippines, certain IRBs have gained 
reputations in terms of how fast they can process applica-
tions. Our participants spoke of knowing exactly which 
boards have fast turnaround times and can be relied 
upon to approve studies with limited timelines. One 
researcher described an IRB based in a private hospital 
as almost “machine-like” in its predictability to approve a 
study swiftly, making it a favorite among those in a hurry 
despite being “less prestigious” than university-based 
boards.
Our participants did identify experiences with efficient 
IRBs that can produce initial results within two weeks 
and finish the whole process in a month. Some also said 
the COVID-19 pandemic has forced IRBs to be more 
efficient—for instance, by finally accepting email sub-
missions and carrying out correspondences accordingly. 
Nevertheless, on the whole, the researchers felt that IRBs 
don’t expedite reviews as often as they should or provide 
more manageable timelines.
Ethics review is costly
Regarding the financial aspect of applying for ethics 
approval, most of our participants said that the cost is 
usually not a problem—so long as the concerned study 
has funding. That said, our interviews showed notable 
variability in the rates that IRBs charge per application. 
Some university boards, for example, completely waive 
their fees for all student and faculty applications, while 
others provide considerable discounts. On average, how-
ever, the fees range between PHP 20,000–50,000 (US$ 
416–1,040), and can go as steep as PHP 80,000 (US$ 
1,664) per application.
Even with funding, our participants admitted to being 
concerned at how these rates eat up a considerable chunk 
of the budget. But for independent and student research-
ers, the grim and obvious implication is that these fees 
must come from their own pockets—leading one public 
health researcher to speculate that the barrier inevita-
bly imposed by these fees may not only be limiting the 
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country’s research landscape to certain circles where 
funding is easily available (e.g. academe), but may also be 
discouraging independent or starting researchers from 
pursuing their work. That participant continued:
As head of [redacted private research firm], even I 
find a fee of PHP 30,000 [US$ 624] exorbitant. But 
I’ve also been approached by friends from abroad, 
PhD students who want to do research in the Philip-
pines, who are just shocked at how much our ethics 
boards want to charge them.
Moreover, precisely because there is no rigid regulation 
enforcing some semblance of uniformity upon IRB rates, 
some participants were concerned that IRBs have been 
taking advantage of this “financial opportunity,” as this 
public health researcher illustrated:
The bill for ethics review can include two items. One 
is the ‘ethics review fee’, which is manageable, say, at 
around PHP 20,000 (US$ 416). But a lot of hospi-
tal boards add the second item, a so-called institu-
tional fee—and that’s where it gets super arbitrary. 
For a project that I did with an American govern-
ment agency, for example, one of our hospital sites 
charged us something close to PHP 100,000 [US$ 
2,081], which was way above what we could have 
expected. When we asked for justification for the fee, 
they couldn’t even provide one, which to us was code 
for, ‘We know you have a lot of money, so cough it up’. 
It’s ironic that so-called ethics boards engage in such 
a gray area of practice.
As that excerpt shows, the apparent inconsistencies in 
and unpredictability of these fees are worrying enough—
but more troubling is the idea that ethics review is fast 
becoming a business. One social scientist said it best:
I’m convinced there is a market for ethics review—
that it can be a lucrative industry if you want to go 
down that path. I mean, reviewers just have to read 
a protocol, comment on it, eventually give a deci-
sion—and the board can earn something like PHP 
50,000 [US$ 1,040] from it? And if they’re fast, it will 
only take a month to do that, even less.
That, in fact, is precisely what a member of a private 
hospital’s in-house board confided:
It’s easy to say that having their own in-house IRB 
can position hospitals as prime movers and innova-
tors when it comes to research. But an IRB is also 
admittedly a huge source of funds. There is so much 
money [to be earned from participating] in multi-
country clinical drug trials. Coming from a private-
hospital standpoint, I’d say that is one very compel-
ling reason to form an IRB.
Ethics committees are concentrated in major cities
Aside from the time and cost, our participants also iden-
tified the concentration of IRBs in Metro Manila as a con-
cern, particularly for researchers based in the provinces. 
A clinical researcher from a major Northern Mindanao 
city, for example, said that in her city, she “wouldn’t know 
of any other ethics board to go to besides the one in my 
hospital.” Likewise, a social scientist from a neighboring 
town said that, as far as his field of research is concerned, 
he always has to go “out of town” to get ethics approval.
Many researchers agreed that the SJREB has been 
a welcome solution for multisited studies. But, as one 
researcher from the DOH noted, this solution has its own 
shortcomings: “One of the earlier challenges [encoun-
tered by SJREB] was resistance from the individual eth-
ics review boards, who felt like they were surrendering 
their power and feared they would not be paid anymore 
individually.” Another public health researcher pointed 
out a second shortcoming of this system: Since the 
SJREB strictly applies only to hospitals under the DOH, 
private institutions can refuse to recognize that blanket 
approval and still require researchers to apply for sepa-
rate approval under their own boards (as was this partici-
pant’s experience). “Instead of going through one board 
[SJREB only], in the span of a year our team ended up 
going through three [including two private institutions 
that acted as described],” that participant said. Thus, up 
to now, the need to obtain ethics approval remains a pre-
liminary obstacle among those whose institutions—or 
cities—do not have their own IRBs.
Ethics review is designed for clinical research
Non-clinical researchers highlighted a pressing concern 
not shared by their clinical counterparts: Their percep-
tion that IRB processes have been designed with clini-
cal research in mind—and therefore inappropriate for 
non-clinical disciplines. Fundamentally, this clinical ori-
entation manifests in the paperwork that IRBs require 
researchers to accomplish. As a public health researcher 
said:
It’s bad enough that [IRBs] that have yet to transi-
tion to digital require you to fill out a ton of paper-
work. But many of those questions and forms are 
actually irrelevant to non-clinical studies. It would 
be more efficient for everyone if, for example, tem-
plate forms were already designed according to spe-
cific types of studies.
This bias is also reflected in IRBs’ compositions—and 
the kind of mindset and expertise, or lack thereof, that 
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members consequently bring into their work. For exam-
ple, one social scientist pointed out how hospital-based 
IRBs are usually composed of clinicians—and therefore
cannot be expected to competently evaluate social 
science researches... [Moreover,] it’s not just a matter 
of board composition—a certain sector being over-
represented or underrepresented—but also a mat-
ter of lack of training. Boards in the Philippines just 
aren’t as interdisciplinary as they ought to be.
As such, to quote a clinician who does mostly qualita-
tive research:
Ethics boards can disapprove or question protocols 
not because they are ethically unsound, but because 
they have subjective qualms over methodology—and 
most of the time these qualms result from the sim-
ple fact that the board members are unfamiliar with 
how that methodology works.
What happens in such cases, a participant from a 
firm that specializes in outsourced processing of hos-
pital-based protocols said, is that IRBs then tend to act 
in a reactionary manner. “They react to what you show 
them rather than knowing the right questions to ask. I’ve 
handled many studies with novel or unfamiliar data-col-
lection tools that got questioned relentlessly over their 
design alone.”
It is easy to see, then, where the complaints regard-
ing IRBs overstepping their mandate or “meddling with 
the study,” to use one participant’s words, are partly 
rooted on—and why, when IRBs justify such ’overreach’ 
by saying that “a study cannot be ethically sound if it is 
not methodologically or technically sound,” researchers 
would not believe them. Across all three sectors, we had 
participants who raised that exact point, identifying the 
frequent overreach of authority on the part of IRBs as a 
major cause of tension between researchers and boards. 
This tension becomes more discernible as one deviates 
farther from clinical research and is most pronounced in 
the social sciences.
More than one social scientist experienced working 
with a board that insisted on written informed consent 
for non-clinical studies on vulnerable populations where 
non-written consent has long been established as the 
safer practice. In one such study, the board refused to 
back down, giving the researcher no choice but to forego 
the project. One researcher working on an ethnographic 
study with indigenous peoples—a field where study pop-
ulations are now recognized as co-generators and co-
owners of the data yielded during fieldwork—related the 
difficulty of convincing an IRB that the biomedical norm 
of destroying data after a certain time was not applica-
ble in this case. A university professor shared how an IRB 
once refused to approve a thesis advisee’s proposal not on 
ethical concerns, but on objections to the methodology:
It was an online survey with nothing particularly 
sensitive about it—I should know because I had 
already vetted it—so after all the back-and-forth 
with the board, I put my foot down and sent them 
a stern letter telling them to stop messing with our 
methodology. They backed down and let the study 
proceed as originally designed.
Ethics review for ethics review’s sake?
Taken together, the above complaints shape Filipino 
researchers’ attitudes toward the ethics approval pro-
cess—and influence decisions on which topics to do 
research on, which IRBs to apply to, and whether to pur-
sue a research idea in the first place. As one social scien-
tist confessed:
It quickly becomes discouraging to do research in 
the country because your mindset, as far as IRBs 
are concerned, is that you will really have to fight to 
get approval. I have had experiments in mind that 
I’ve had to abandon over the mere thought that I 
wouldn’t get approved.
Given how the ethics review landscape is only in its 
relative infancy, the same participant continued, “the way 
these boards are operating right now, it’s almost like they 
think they’re at a dissertation defense and researchers are 
there to defend their study.”
“Here in the Philippines it’s almost as if IRBs are dictat-
ing to researchers, treating them like they don’t know any 
better,” said the head of a private research firm, going on 
to say how
it becomes difficult to accept that kind of treatment 
when you know these boards are not perfect them-
selves. The worst experience I’ve had was when a 
study was returned to me after quite some time with 
comments that had absolutely nothing to do with my 
paper—because they were meant for another study.
Such experiences have led researchers to adopt a prag-
matic view of ethics: as a necessary, if bureaucratic, step 
in their projects. “We only look at two things,” a private-
sector researcher said, “fast turnaround times and inex-
pensive costs.”
A public health researcher separately added that the 
ethics review process is all about working toward an 
approval, and the moment that approval is obtained, the 
whole process abruptly comes to an end: There is usu-
ally no active follow-up from the IRBs during the course 
of fieldwork and beyond, even as the requirements for 
approval emphasize the necessity of such a process; in 
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fact, most of the time, the burden of follow-up falls on 
the researchers themselves, who end up actively updating 
the boards regarding their progress. In this sense, eth-
ics approval is reduced to a mere piece of paper, some-
thing to be obtained, rather than a thorough evaluation 
of the conduct and impact of the study both from within 
and without. In the end, that same researcher said, the 
demands of IRB application processes take away time 
that would have been better devoted to preparing for the 
actual analysis, writing, and publication of a study.
In fact, some participants fear that ethics boards may 
be fomenting a culture of gatekeeping insofar as research 
is concerned, given their lack of accountability. Despite 
the existence of PHREB, these researchers complain that 
there is no feedback mechanism to air their concerns 
regarding the approval process and no discernible metric 
system to evaluate the performance of IRBs.
In many ways, all these criticisms are reflective not only 
of IRB practices in the country, but of the larger research 
landscape. Commenting on the inordinate amount of 
time it takes IRBs to process applications, a participant 
from a firm specializing in outsourced processing of hos-
pital-based protocols said:
The perfect way to describe our research landscape is 
that there is a lot of research waste going on, and it’s 
all rooted in the lack of protected time for research. 
I’ve seen how it is in other countries, where even jun-
ior researchers are really given protected time to do 
research, where the whole system is very accessible. 
Here, the fact that we don’t have such dedicated 
time already affects the quality of writing in our pro-
tocols to begin with.
“Ethics should be ingrained in every researcher and 
must go beyond the IRB,” said a social scientist. At the 
very least, that same scientist said,
IRBs should place a certain  level of trust on the 
researchers they are working with  or the technical 
review boards who have separately screened the pro-
tocols... Right now, how IRBs are shaping the way we 
do research is in the mode of ‘I’ll develop a research 
protocol that will be so benign, it will be immedi-
ately approved by an ethics committee’, instead of 
‘I will be making a protocol that will not affect the 
lives, health, and well-being of my respondents’. 
Those are two completely different things.
Counterpoint: perspectives of IRB members
From the standpoint of researchers who have worked 
in or are currently members of IRBs, the logistical limi-
tations of IRBs can be explained by the simple fact 
that unlike other countries, the Philippines has yet to 
professionalize research ethics. One participant said one 
of the birthing pains of “building a culture of research 
ethics” is getting people to appreciate and participate in 
research ethics, to serve as reviewers and panel mem-
bers. A participant from the DOH observed how “most 
hospitals have no actual budget dedicated to sustaining 
an ethics board. That is why ethics boards become highly 
dependent on the fees that they charge to, say, pay for the 
office space, the secretariat and administrative staff, etc.” 
As a clinician-researcher put it:
The operation of IRBs is governed by a lot of privacy 
and confidentiality. But even in big universities, 
we are not always assured of lockable cabinets. We 
should not be sharing a fax machine with another 
office. We should have our own shredder.
Protracted turnaround times can be easily explained by 
the fact that IRBs are often understaffed and swamped 
with protocols. Almost always, IRB members also have 
other responsibilities, such as being university profes-
sors or clinicians, and cannot devote all of their working 
time to just evaluating protocols. Almost always, as well, 
the compensation for IRB members is hardly commensu-
rate to the amount of time and effort that they devote to 
the work. One participant described present conditions 
succinctly:
Reviewers are asked to read 300-page protocols and 
paid for only an hour of the job. So you really have 
to question why, in a clinical trial, for example, an 
IRB would charge PHP 60,000–70,000 [US$ 1,250–
1,455] for review but pay its reviewers only PHP 
1,000–2,000 [US$ 20–42] per protocol reviewed.
Where the perspectives of IRB members diverge from 
our other participants is in the mandate of an IRB. “Many 
researchers cling to this belief that ethics boards are bar-
riers to research,” said one board member. “Research-
ers tend to become preoccupied with the science of 
their protocols and end up ignoring the ethics of their 
protocols.”
According to this subset of participants, a lot of the 
back-and-forth that researchers complain about in their 
dealings with IRBs has to do with the simple fact that 
these protocols tend to be badly written. Researchers can 
overlook the major, complicated issues such as the study 
design, but, as one participant noted, the oversight can 
be far simpler: “I have received studies that, in the objec-
tives, stated the intent to compare this and that, but this 
intent to compare is not even reflected at all in the study 
design.”
They also emphasize that the existence of technical 
review boards is not an excuse for IRBs to be less strict. 
According to one participant,
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preliminary technical review is helpful, but in my 
experience, most of the time it pays for me as an 
ethics reviewer to also assess the technical aspects 
simply because the technical review can miss out 
on a lot of things that then make the study ethically 
unsound.
Ideally, that participant continued, if the finances and 
manpower can make it possible, only one committee 
should do both ethical and technical reviews to stream-
line the whole process. In the end, another participant 
said,
researchers don’t realize that when an IRB ‘over-
steps’ and points out technical issues, it’s not because 
of overreach or a matter of gatekeeping. It’s because 
as an IRB member, you realize that the study goes 
beyond the researcher; it will affect individuals and 
communities.
A social scientist belonging to an IRB provided this 
illustrative summary to the argument:
Let’s say you are doing a study on the impact of 
COVID to mental health. If you settle for 400 as 
your study population, imagine asking 400 people 
these intrusive questions that would only magnify 
the risks that they may have already been exposed 
to. Inserting ethics into the question makes you ask, 
for example, whether you can achieve the same 
results with half the population size. It makes you 
think about the responsibilities of a researcher, so 
before you submit your protocol for approval, you 
are already considering the soundness of the design 
and other questions that you would have otherwise 
ignored if you were solely focused on the science.
Discussion
An issue of inequity
On the whole, our study resonates with the global lit-
erature that have examined—and/or have been critical 
of—the role, culture, and practices of research ethics 
committees, beginning with an acknowledgment of their 
necessity: Faced with the prospect of ethical review, most 
of our participants echoed Schrag’s observation, in that 
their first instinct is generally one of “eager cooperation.” 
[16] (p. 122)
But as our findings also showed, the rift between 
the perspectives of researchers and IRBs regarding the 
review process transcends mere diverging views on what 
constitutes “ethical research.” And in any case, the prob-
lems raised by Filipino researchers regarding that process 
are only part of the continuum of ongoing debates world-
wide—from the time-consuming and paperwork-heavy 
nature of ethics approval described by Gold and Dewa 
[17] in their study of multisited researches; imbalances 
in board composition that, as Schuppli and Fraser [18] 
wrote, render evaluations ineffective; and the highly clini-
cal framework of current review processes that Flicker 
et al. have criticized for possibly doing more harm than 
good and “placing communities at risk” through an 
insistence on inappropriate measures of evaluation, par-
ticularly as imposed upon the social sciences and par-
ticipatory research [19]. To go by Abbott and Grady, the 
Philippine situation is similarly riddled with all forms of 
inefficiencies and inconsistencies, be it in terms of appli-
cation fees, duration of review, or outcomes of evalua-
tions [20]. Additionally, although our limited findings 
disallow us from fully arriving at the same, incontrovert-
ible conclusion, the anecdotes of our participants regard-
ing commercial IRBs nonetheless find some measure of 
resonance in Lemmens and Freedman [21], who, a full 
two decades earlier, already voiced concerns regarding 
profit-related conflicts of interests as regards the opera-
tion of these ethics boards, and how these conflicts may 
eventually compromise the quality of review and erode 
public trust in IRBs.
In its most fundamental sense, then, ethics review is 
an issue of inequity. The existing system serves as yet 
another barrier for those outside the academe; those 
belonging to institutions, cities, or entire regions with-
out their own accredited IRBs; and researchers working 
independently, without ample budget, or on highly spe-
cialized topics. And even for researchers affiliated with 
institutions that have their own IRBs, the balance invari-
ably tips toward those with sufficient funding and/or 
those working on topics that tend to receive funding. All 
of these contribute to the rise of what Patterson [22] calls 
“spaces of marginalization” that privilege certain types 
of research, and research topics—and eventually, knowl-
edge production—over others.
As our own research demonstrates, non-clinical 
researchers find themselves at the marginal end of that 
divide. For these researchers, the inequitable landscape is 
also one where they must abide by what Schrag describes 
as “silly restrictions” that are inapplicable to their respec-
tive fields, and which are imposed mostly by IRBs that 
lack the expertise to properly evaluate protocols and end 
up applying “inappropriate” principles to such evalua-
tions [16]. Often, IRBs operating on a highly biomedical 
framework have exaggerated “protectionist concerns,” 
[23] (p. 483) the imposition of which do not necessarily 
result in more ethical research practices [24]. Instead, 
in such a landscape, current guidelines may only serve 
to actually “[impede] ethically sound or potentially ben-
eficial research,” [25] (p. 161) and may be entirely unable 
to address more complex, field-related situations already 
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raised by existing scholarship [26]—further straining 
researcher-IRB relations and aggravating researchers’ 
feelings of mistrust, if not outright antagonism [27, 28]. 
At worst, this “unquestioning transposition of ethical 
principles from [clinical to non-clinical] research [may] 
lead to inappropriate practices that… actually encourage 
less ethical practice.” [24] (pp. 94–95).
Ultimately the demands that the ethics application pro-
cess imposes upon researchers cannot simply be reduced 
to discrete complaints—on matters of time, or finances, 
or geographical proximity, or expertise from the side 
of IRBs; it is an interplay of these factors that breeds an 
environment that favors those with the resources to do 
research—and those with researches that are more likely 
to attract funding. In this manner, indeed, the ethics 
review process becomes a matter of (in)equity.
Recommendations
While the broader challenge of equity in health research 
will entail more fundamental reforms (as detailed by 
Pratt, Merritt and Hyder [29]), more proximal interven-
tions can be done to improve the research ethics process 
and make it more equitable. For instance, an oversight 
committee—in the case of the Philippines, PHREB—
should take a more proactive role in mediating the 
debates of research culture, and go far and beyond its 
mandate to promote the proliferation and evaluate the 
performance of IRBs—with special emphasis on what 
Coleman and Bouësseau [30] term outcomes assess-
ment, or ensuring from the IRBs’ end that so-called ethi-
cal research actually carries on to the field. This is not to 
undermine the trust between researchers and IRBs once 
a research has been approved, but to say that IRBs that 
require researchers to submit regular updates during data 
gathering, for example, should also be more proactive 
in seeking those updates or tackling unforeseen ethical 
dilemmas that may arise after protocol review. Else, what 
persists is the image of ethics approval as the ‘golden calf ’ 
of the research process, a mere objective to be attained 
and surmounted.
Moreover, such a committee could also act as a 
mediator in the financial burden of ethics review—for 
example, by regulating and imposing uniformity on 
fees—thereby potentially eliminating conflicts of interest 
where money and/or power relations is concerned, mak-
ing ethics approval more equitable while still allowing 
IRBs a comfortable measure of financial self-sufficiency 
(see, for example, the arguments of Emanuel, Lemmens 
and Elliot [31]). That the complaints of our participants 
who have worked or are part of IRBs centered mostly 
around the lack of material support (in terms of person-
nel, office resources, and/or protected, compensated time 
for IRB-related duties) only makes this kind of financial 
self-sufficiency an imperative—and all the more so when 
one considers how this problem has been perennially rec-
ognized across global literature [20, 32].
For researchers, the institutions they represent, and 
IRBs, the spirit of equity should extend to supporting 
research topics that have not enjoyed as much scholarly 
attention and making the landscape more hospitable 
for early-career, student, and independent researchers. 
To paraphrase Chatfield et  al. [33], making this pos-
sible includes ensuring that IRBs are staffed with the 
right kind of ‘qualified experts’—given that there are “no 
absolute standards upon which IRBs can rely [in evalu-
ating protocols]” and ethics boards must therefore bank 
on “a fair exercise of intelligence and discretion on the 
part of [their] members” [21] (p. 562)—and lessening the 
bureaucratic roadblocks that make even getting ethics 
approval already a laborious process. To recapitulate a 
point made earlier, a change in research culture requires 
not taking time away from the actual conduct of the 
study—from data gathering, analysis, and paper writing. 
In other words, fostering “a culture of ethics” instead of 
“a culture of red tape,” to quote Burris and Welsh in Cole-
man and Bouësseau [30] (p. 4).
Doing so eventually boils down to the kind of larger 
research culture that we foster,  where: (1) research is 
seen as an integral part of knowledge production, in 
the academe as in other fields of society, and therefore 
granted protected time and sufficient funding; (2) IRBs 
are seen as instrumental partners in research and there-
fore granted sufficient human, material, and financial 
resources to fulfill their mandate; (3) “ethical research” is 
not viewed as culminating in IRB approval, but as foun-
dational to research—and practiced deliberately, from the 
writing of the study protocol to the final study analysis; 
and (4) a certain level of ‘trust’ is established between 
researchers and IRBs [34, 35], manifesting not through 
what Makhoul [36] aptly labels “policing,” but through 
a “collaborative and supportive relationship” that makes 
‘allies’ out of IRBs and researchers [32].
Conclusion
Our study has certain limitations. First of all, our lim-
ited sample size means that our findings cannot be 
interpreted as unequivocal generalizations of the health 
research landscape in the Philippines, or even as defini-
tive pictures of each sub-field of health research as far 
as IRBs are concerned. Moreover, almost all of our par-
ticipants hailed from Metro Manila, making it impos-
sible to account for specific experiences in the country’s 
many other cities and regions, given the variability in 
academic and research culture across the nation. Our 
participants’ affiliations were likewise limiting: We had 
no interviewees who were undergraduate students, 
Page 10 of 11Lasco et al. BMC Med Ethics           (2021) 22:85 
for instance, and nearly half of our participants were 
affiliated with the state-funded UP system—a fact that 
would have no doubt colored our participants’ careers 
and narratives. The focus of our study itself—IRBs in 
the context of health research—disallows our findings 
from being considered as entirely valid conclusions 
for other fields of academic, and even non-academic, 
research in the country. As such, future avenues for 
research may include IRB culture and practices in non-
health research, as well as the relative infancy of multis-
ited common review in the country.
Nevertheless, our study shows how the case of the 
Philippines can serve as a point of reflection for simi-
lar low- and middle-income countries where research 
inequities have persisted. The narratives of our par-
ticipants show how, despite growing recognition of 
the fundamental role of IRBs to research ethics, the 
research landscape remains one that is riddled with 
structural biases and deficiencies—problems that are 
challenging to overcome, but which are definitely not 
without solutions. Arguing that ethics review is essen-
tial even for non-medical research, Lindoff [37] calls 
for opening up lines of dialogue between researchers 
and IRBs, highlighting the importance of such partner-
ship between the two parties. To this, we concur—but 
with the caveat that such a partnership may flourish 
only when the ethics approval process ceases to be a 
barrier for researchers. Should a middle ground exist, 
it should be one where researchers need not surmount 
numerous structural inequities even before a study 
has commenced; one where researchers don’t have to 
“fight” for ethics approval.
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